A review of imlifidase in solid organ transplantation

References

• Kissmeyer-Nielsen F, Olsen S, Petersen VP, et al. Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells. Lancet. 1966 Sep 24;2(7465):662–665. PubMed PMID: 4162350.
   PubMed Web of Science ®Google Scholar
• Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med. 1969 Apr 3;280(14):735–739. PubMed PMID: 4886455.
   PubMed Web of Science ®Google Scholar
• Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999 Dec 2;341(23):1725–1730. PubMed PMID: 10580071.
   PubMed Web of Science ®Google Scholar
• Orandi BJ, Luo X, Massie AB, et al. Survival benefit with kidney transplants from HLA-incompatible live donors. N Engl J Med. 2016 Mar 10;374(10):940–950. PubMed PMID: 26962729; PubMed Central PMCID: PMCPMC4841939.
   PubMed Web of Science ®Google Scholar
• Organ Procurement and Transplantation Network. https://optn.transplant.hrsa.gov/media/1200/optn_policies.pdf
   Google Scholar
• Jackson KR, Covarrubias K, Holscher CM, et al. The national landscape of deceased donor kidney transplantation for the highly sensitized: transplant rates, waitlist mortality, and posttransplant survival under KAS. Am J Transplant. 2019 Apr;19(4):1129–1138. PubMed PMID: 30372592; PubMed Central PMCID: PMCPMC6433516.
   PubMed Web of Science ®Google Scholar
• Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med. 2008 Jul 17;359(3):242–251. PubMed PMID: 18635429.
   PubMed Web of Science ®Google Scholar
• Alachkar N, Lonze BE, Zachary AA, et al. Infusion of high-dose intravenous immunoglobulin fails to lower the strength of human leukocyte antigen antibodies in highly sensitized patients. Transplantation. 2012 Jul 27;94(2):165–171. PubMed PMID: 22735712.
   PubMed Web of Science ®Google Scholar
• Jordan SC, Tyan D, Stablein D, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol. 2004 Dec;15(12):3256–3262. PubMed PMID: 15579530.
   PubMed Web of Science ®Google Scholar
• Sethi S, Choi J, Toyoda M, et al. Desensitization: overcoming the Immunologic Barriers to Transplantation. J Immunol Res. 2017;2017:6804678. PubMed PMID: 28127571; PubMed Central PMCID: PMCPMC5239985 Jordan has research grants from CSL-Behring and Genentech and has served as a consultant for CSL-Behring, Genentech, and Bristol Myers Squib, Inc.
   PubMed Web of Science ®Google Scholar
• Vo AA, Petrozzino J, Yeung K, et al. Efficacy, outcomes, and cost-effectiveness of desensitization using IVIG and rituximab. Transplantation. 2013 Mar 27;95(6):852–858. PubMed PMID: 23511212.
   PubMed Web of Science ®Google Scholar
• Segev DL, Gentry SE, Melancon JK, et al. Characterization of waiting times in a simulation of kidney paired donation. Am J Transplant. 2005 Oct 5;5(10):2448–2455. PubMed PMID: 16162194.
   PubMed Web of Science ®Google Scholar
• Segev DL, Gentry SE, Warren DS, et al. Kidney paired donation and optimizing the use of live donor organs. JAMA. 2005 Apr 20;293(15):1883–1890. PubMed PMID: 15840863.
   PubMed Web of Science ®Google Scholar
• Flechner SM, Thomas AG, Ronin M, et al. The first 9 years of kidney paired donation through the national kidney registry: characteristics of donors and recipients compared with national live donor transplant registries. Am J Transplant. 2018 Nov;18(11):2730–2738. PubMed PMID: 29603640; PubMed Central PMCID: PMCPMC6165704.
   PubMed Web of Science ®Google Scholar
• Kumlien G, Ullstrom L, Losvall A, et al. Clinical experience with a new apheresis filter that specifically depletes ABO blood group antibodies. Transfusion. 2006 Sep;46(9):1568–1575. PubMed PMID: 16965585.
   PubMed Web of Science ®Google Scholar
• Genberg H, Kumlien G, Wennberg L, et al. The efficacy of antigen-specific immunoadsorption and rebound of anti-A/B antibodies in ABO-incompatible kidney transplantation. Nephrol Dial Transplant. 2011 Jul;26(7):2394–2400. PubMed PMID: 21558429.
   PubMed Web of Science ®Google Scholar
• Rydberg L, Bengtsson A, Samuelsson O, et al. In vitro assessment of a new ABO immunosorbent with synthetic carbohydrates attached to sepharose. Transpl Int. 2005 Jan;17(11):666–672. PubMed PMID: 15551052.
   PubMed Web of Science ®Google Scholar
• Palmer A, Taube D, Welsh K, et al. Removal of anti-HLA antibodies by extracorporeal immunoadsorption to enable renal transplantation. Lancet. 1989 Jan 7;1(8628):10–12. PubMed PMID: 2563001.
   PubMed Web of Science ®Google Scholar
• Hakim RM, Milford E, Himmelfarb J, et al. Extracorporeal removal of anti-HLA antibodies in transplant candidates. Am J Kidney Dis. 1990 Nov;16(5):423–431. PubMed PMID: 2239932.
   PubMed Web of Science ®Google Scholar
• Reisaeter AV, Leivestad T, Albrechtsen D, et al. Pretransplant plasma exchange or immunoadsorption facilitates renal transplantation in immunized patients. Transplantation. 1995 Aug 15;60(3):242–248. PubMed PMID: 7645036.
   PubMed Web of Science ®Google Scholar
• Ronspeck W, Brinckmann R, Egner R, et al. Peptide based adsorbers for therapeutic immunoadsorption. Ther Apher Dial. 2003 Feb 7;7(1):91–97. PubMed PMID: 12921122.
   PubMed Web of Science ®Google Scholar
• Holscher CM, Jackson KR, Segev DL. Transplanting the Untransplantable. Am J Kidney Dis. 2020 Jan;75(1):114–123. PubMed PMID: 31255336.
   PubMed Web of Science ®Google Scholar
• Montgomery RA, Lonze BE, King KE, et al. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med. 2011 Jul 28;365(4):318–326. PubMed PMID: 21793744.
   PubMed Web of Science ®Google Scholar
• Orandi BJ, Garonzik-Wang JM, Massie AB, et al. Quantifying the risk of incompatible kidney transplantation: a multicenter study. Am J Transplant. 2014 Jul;14(7):1573–1580. PubMed PMID: 24913913.
   PubMed Web of Science ®Google Scholar
• Schold JD, Arrington CJ, Levine G. Significant alterations in reported clinical practice associated with increased oversight of organ transplant center performance. Prog Transplant. 2010 Sep;20(3):279–287. PubMed PMID: 20929114.
   PubMed Web of Science ®Google Scholar
• Kasiske BL, Salkowski N, Wey A, et al. Potential implications of recent and proposed changes in the regulatory oversight of solid organ transplantation in the United States. Am J Transplant. 2016 Dec;16(12):3371–3377. PubMed PMID: 27401597; PubMed Central PMCID: PMCPMC5233595.
   PubMed Web of Science ®Google Scholar
• Chandraker A, Andreoni KA, Gaston RS, et al. Time for reform in transplant program-specific reporting: AST/ASTS transplant metrics taskforce. Am J Transplant. 2019 Jul;19(7):1888–1895. PubMed PMID: 31012525.
   PubMed Web of Science ®Google Scholar
• Chang P, Gill J, Dong J, et al. Living donor age and kidney allograft half-life: implications for living donor paired exchange programs. Clin J Am Soc Nephrol. 2012 May 7;7(5):835–841. PubMed PMID: 22442187; PubMed Central PMCID: PMCPMC3338279.
   PubMed Web of Science ®Google Scholar
• Sapir-Pichhadze R, Tinckam KJ, Laupacis A, et al. Immune sensitization and mortality in wait-listed kidney transplant candidates. J Am Soc Nephrol. 2016 Feb;27(2):570–578. PubMed PMID: 26054537; PubMed Central PMCID: PMCPMC4731107.
   PubMed Web of Science ®Google Scholar
• von Pawel-rammingen U, Johansson BP, Bjorck L. IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G. Embo J. 2002 Apr 2;21(7):1607–1615. PubMed PMID: 11927545; PubMed Central PMCID: PMCPMC125946.
   PubMed Web of Science ®Google Scholar
• Lei B, DeLeo FR, Hoe NP, et al. Evasion of human innate and acquired immunity by a bacterial homolog of CD11b that inhibits opsonophagocytosis. Nat Med. 2001 Dec 7;7(12):1298–1305. PubMed PMID: 11726969.
   PubMed Web of Science ®Google Scholar
• Vincents B, von Pawel-rammingen U, Bjorck L, et al. Enzymatic characterization of the streptococcal endopeptidase, IdeS, reveals that it is a cysteine protease with strict specificity for IgG cleavage due to exosite binding. Biochemistry. 2004 Dec 14;43(49):15540–15549. PubMed PMID: 15581366.
   PubMed Web of Science ®Google Scholar
• Agniswamy J, Lei B, Musser JM, et al. Insight of host immune evasion mediated by two variants of group a Streptococcus Mac protein. J Biol Chem. 2004 Dec 10;279(50):52789–52796. PubMed PMID: 15466462.
   PubMed Web of Science ®Google Scholar
• Johansson BP, Shannon O, Bjorck L. IdeS: a bacterial proteolytic enzyme with therapeutic potential. PLoS One. 2008 Feb 27;3(2):e1692. PubMed PMID: 18301769; PubMed Central PMCID: PMCPMC2253494.
   PubMed Web of Science ®Google Scholar
• Nandakumar KS, Johansson BP, Bjorck L, et al. Blocking of experimental arthritis by cleavage of IgG antibodies in vivo. Arthritis Rheum. 2007 Oct;56(10):3253–3260. PubMed PMID: 17907170.
   PubMedGoogle Scholar
• Yang R, Otten MA, Hellmark T, et al. Successful treatment of experimental glomerulonephritis with IdeS and EndoS, IgG-degrading streptococcal enzymes. Nephrol Dial Transplant. 2010 Aug;25(8):2479–2486. PubMed PMID: 20219834.
   PubMed Web of Science ®Google Scholar
• Winstedt L, Jarnum S, Nordahl EA, et al. Complete removal of extracellular igg antibodies in a randomized dose-escalation phase I study with the bacterial enzyme IdeS–A novel therapeutic opportunity. PLoS One. 2015;10(7):e0132011. PubMed PMID: 26177518; PubMed Central PMCID: PMCPMC4503742.
   PubMed Web of Science ®Google Scholar
• van Hage M, Hamsten C, Valenta R. ImmunoCAP assays: pros and cons in allergology. J Allergy Clin Immunol. 2017 Oct;140(4):974–977. PubMed PMID: 28552762.
   PubMed Web of Science ®Google Scholar
• Akesson P, Rasmussen M, Mascini E, et al. Low antibody levels against cell wall-attached proteins of Streptococcus pyogenes predispose for severe invasive disease. J Infect Dis. 2004 Mar 1;189(5):797–804. PubMed PMID: 14976595.
   PubMed Web of Science ®Google Scholar
• Lorant T, Bengtsson M, Eich T, et al. Safety, immunogenicity, pharmacokinetics, and efficacy of degradation of anti-HLA antibodies by IdeS (imlifidase) in chronic kidney disease patients. Am J Transplant. 2018 Nov;18(11):2752–2762. PubMed PMID: 29561066; PubMed Central PMCID: PMCPMC6221156.
   PubMed Web of Science ®Google Scholar
• Jordan SC, Lorant T, Choi J. IgG endopeptidase in highly sensitized patients undergoing transplantation. N Engl J Med. 2017 Oct 26;377(17):1693–1694. PubMed PMID: 29083132.
   PubMedGoogle Scholar
• Lonze BE, Tatapudi VS, Weldon EP, et al. IdeS (Imlifidase): a novel agent that cleaves human IgG and permits successful kidney transplantation across high-strength donor-specific antibody. Ann Surg. 2018 Sep;268(3):488–496. PubMed PMID: 30004918.
   PubMed Web of Science ®Google Scholar
• A phase II study to evaluate the efficacy of IdeS to desensitize transplant patients with a positive crossmatch test (Highdes). NCT02790437. https://clinicaltrials.gov
   Google Scholar
• Jordan SC, Legendre C, Desai NM, et al. Imlifidase desensitization in crossmatch-positive, highly-sensitized kidney transplant recipients: results of an international phase 2 trial (Highdes). Transplantation. 2020 Oct 21;Publish Ahead of Print. PubMed PMID: 33093408.
   Google Scholar
• Fuquay R, Renner B, Kulik L, et al. Renal ischemia-reperfusion injury amplifies the humoral immune response. J Am Soc Nephrol. 2013 Jun;24(7):1063–1072. PubMed PMID: 23641055; PubMed Central PMCID: PMCPMC3699821.
   PubMed Web of Science ®Google Scholar
• Jackson AM, Kraus ES, Orandi BJ, et al. A closer look at rituximab induction on HLA antibody rebound following HLA-incompatible kidney transplantation. Kidney Int. 2015 Feb;87(2):409–416. PubMed PMID: 25054778; PubMed Central PMCID: PMCPMC4305036.
   PubMed Web of Science ®Google Scholar
• Montgomery RA, Locke JE, King KE, et al. ABO incompatible renal transplantation: a paradigm ready for broad implementation. Transplantation. 2009 Apr 27;87(8):1246–1255. PubMed PMID: 19384174.
   PubMed Web of Science ®Google Scholar
• Montgomery JR, Berger JC, Warren DS, et al. Outcomes of ABO-incompatible kidney transplantation in the United States. Transplantation. 2012 Mar 27;93(6):603–609. PubMed PMID: 22290268; PubMed Central PMCID: PMCPMC3299822.
   PubMed Web of Science ®Google Scholar
• Lonze BE, Bae S, Kraus ES, et al. Outcomes and risk stratification for late antibody-mediated rejection in recipients of ABO-incompatible kidney transplants: a retrospective study. Transpl Int. 2017 Sep;30(9):874–883. PubMed PMID: 28403566.
   PubMed Web of Science ®Google Scholar
• Held PJ, McCormick F. ABO-incompatible kidney transplants: twice as expensive, half as good. Am J Transplant. 2016 May;16(5):1343–1344. PubMed PMID: 26614637.
   PubMed Web of Science ®Google Scholar
• Ge S, Chu M, Choi J, et al. Imlifidase inhibits HLA antibody-mediated NK cell activation and antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro. Transplantation. 2020 Aug;104(8):1574–1579. PubMed PMID: 32732834.
   PubMed Web of Science ®Google Scholar
• An Efficacy and Safety Study of Imlifidase in Treatment of Antibody-Mediated Rejection in Kidney Transplant Patients. NCT03897205. http://clinicaltrials.gov
   Google Scholar
• Berry GJ, Burke MM, Andersen C, et al. The 2013 international society for heart and lung transplantation working formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation. J Heart Lung Transplant. 2013 Dec;32(12):1147–1162. PubMed PMID: 24263017.
   PubMed Web of Science ®Google Scholar
• Del Bello A, Neau-Cransac M, Lavayssiere L, et al. Outcome of liver transplant patients with preformed donor-specific anti-human leukocyte antigen antibodies. Liver Transpl. 2020 Feb;26(2):256–267. PubMed PMID: 31612580.
   PubMed Web of Science ®Google Scholar
• Colvin MM, Cook JL, Chang P, et al. Antibody-mediated rejection in cardiac transplantation: emerging knowledge in diagnosis and management: a scientific statement from the American Heart Association. Circulation. 2015 May 5;131(18):1608–1639. PubMed PMID: 25838326.
   PubMed Web of Science ®Google Scholar
• Lee M. Antibody-mediated rejection after liver transplant. Gastroenterol Clin North Am. 2017 Jun;46(2):297–309. PubMed PMID: 28506366.
   PubMed Web of Science ®Google Scholar
• Levine DJ, Glanville AR, Aboyoun C, et al. Antibody-mediated rejection of the lung: a consensus report of the International society for heart and lung transplantation. J Heart Lung Transplant. 2016 Apr;35(4):397–406. PubMed PMID: 27044531.
   PubMed Web of Science ®Google Scholar
• Parulekar AD, Kao CC. Detection, classification, and management of rejection after lung transplantation. J Thorac Dis. 2019 Sep;11(Suppl14):S1732–S1739. PubMed PMID: 31632750; PubMed Central PMCID: PMCPMC6783728.
   PubMedGoogle Scholar
• Kransdorf EP, Kittleson MM, Patel JK, et al. Calculated panel-reactive antibody predicts outcomes on the heart transplant waiting list. J Heart Lung Transplant. 2017 Jul;36(7):787–796. PubMed PMID: 28318744.
   PubMed Web of Science ®Google Scholar